Genetic testing strategies for neonatal cholestasis in the neonatal intensive care unit

OBJECTIVES: Cholestasis in the Neonatal Intensive Care Unit (NICU) has a broad differential diagnosis, including genetic diseases. Advances in next generation sequencing (NGS) have expanded the ability to identify genetic etiologies. Studies evaluating testing strategies, diagnostic yield, and clinical characteristics of those undergoing genetic testing for cholestasis in the NICU are limited. METHODS: We retrospectively studied patients at a single-center Level IV NICU with cholestasis, genetic testing and Hepatology consultation between January 1, 2015, and December 31, 2024. Microarray, targeted gene panel and exome or genome sequencing (ES/GS) results and clinical characteristics of those tested were reviewed. Diagnostic yield was defined as identification of pathogenic variants determined to be causative of cholestasis. Categorical variables were compared using Chi-squared test or Fisher's exact as appropriate. Continuous variables were compared using Wilcoxon rank sum tests or Kruskal-Wallis tests as appropriate. RESULTS: A total of 174 patients were included for analysis. Patients with three modalities of testing had higher peak direct bilirubin and alanine aminotransferase. Diagnostic yield increased by comprehensiveness: microarray 5% (3/54), targeted gene panel 10% (12/125) and ES/GS 33% (23/70). Seven patients with non-diagnostic targeted panels had diagnostic ES/GS. Those with diagnostic ES/GS were younger at Hepatology consultation, had higher peak direct bilirubin and were less likely to have sepsis compared to those with diagnostic targeted panels. CONCLUSIONS: ES/GS demonstrated greater diagnostic yield for cholestasis in the NICU than other modalities. Confounding by year of testing is possible, but differences in yield support preferential use of ES/GS for neonatal cholestasis evaluation.

Authors

Institutions

Publication Details

Journal
Journal of Pediatric Gastroenterology and Nutrition
Published
2026-11-17
DOI
https://doi.org/10.1002/jpn3.70696
Primary Topic
Pediatric Hepatobiliary Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Genetic testing strategies for neonatal cholestasis in the neonatal intensive care unit

Alyshah Lakhani, Carol Potter, Alexander Weymann, Bimal Pankaj Chaudhari et al.
2 links
Journal of Pediatric Gastroenterology and Nutrition
Pediatric Hepatobiliary Diseases and Treatments
article

Genetic testing strategies for neonatal cholestasis in the neonatal intensive care unit

Alyshah Lakhani, Carol Potter, Alexander Weymann, Bimal Pankaj Chaudhari, Alvin Jay Freeman, Shivam Joshi, Sarah Balster
article en

Abstract

OBJECTIVES: Cholestasis in the Neonatal Intensive Care Unit (NICU) has a broad differential diagnosis, including genetic diseases. Advances in next generation sequencing (NGS) have expanded the ability to identify genetic etiologies. Studies evaluating testing strategies, diagnostic yield, and clinical characteristics of those undergoing genetic testing for cholestasis in the NICU are limited. METHODS: We retrospectively studied patients at a single-center Level IV NICU with cholestasis, genetic testing and Hepatology consultation between January 1, 2015, and December 31, 2024. Microarray, targeted gene panel and exome or genome sequencing (ES/GS) results and clinical characteristics of those tested were reviewed. Diagnostic yield was defined as identification of pathogenic variants determined to be causative of cholestasis. Categorical variables were compared using Chi-squared test or Fisher's exact as appropriate. Continuous variables were compared using Wilcoxon rank sum tests or Kruskal-Wallis tests as appropriate. RESULTS: A total of 174 patients were included for analysis. Patients with three modalities of testing had higher peak direct bilirubin and alanine aminotransferase. Diagnostic yield increased by comprehensiveness: microarray 5% (3/54), targeted gene panel 10% (12/125) and ES/GS 33% (23/70). Seven patients with non-diagnostic targeted panels had diagnostic ES/GS. Those with diagnostic ES/GS were younger at Hepatology consultation, had higher peak direct bilirubin and were less likely to have sepsis compared to those with diagnostic targeted panels. CONCLUSIONS: ES/GS demonstrated greater diagnostic yield for cholestasis in the NICU than other modalities. Confounding by year of testing is possible, but differences in yield support preferential use of ES/GS for neonatal cholestasis evaluation.

Journal of Pediatric Gastroenterology and Nutrition
Nationwide Children's Hospital (US), The Ohio State University (US)
Good health and well-being
Pediatric Hepatobiliary Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon